Business
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21
About this update from Nanobiotix Sa
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/w.WG45QhRIjOjkLYfarG8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.1","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"78.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.1","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"14.6 months median Overall Survival (mOS) in all patients treated (n=21)","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Nanobiotix will host a conference call to discuss the data on September 18, 2025 at 8:00AM EDT/ 2:00PM CEST","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":811,"olType":false},{"type":"text","content":"Data presented on September 17 at the 2025 Immunorad Conference","length":63,"tagName":"p"},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new results focused on patients with primary cutaneous melanoma...